| NAI for Sepsis With Persistent Lymphopenia (NCT07578558) | ImmunityBio, Inc. | 2026-07-06 |
| Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer (NCT07488884) | ImmunityBio, Inc. | 2026-06-01 |
| ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer (NCT07551544) | ImmunityBio, Inc. | 2026-05-15 |
| Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia (NCT07492875) | ImmunityBio, Inc. | 2026-04-15 |
| Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) (NCT07492888) | ImmunityBio, Inc. | 2026-04-15 |
| Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma (NCT07477366) | ImmunityBio, Inc. | 2026-04-01 |
| Immunotherapy Before and After Surgery (NCT06765902) | ImmunityBio, Inc. | 2025-12-15 |
| A Study to Assess Anktiva in Patients With Long Covid-19. (NCT07108036) | ImmunityBio, Inc. | 2025-11-14 |
| Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma (NCT07125872) | ImmunityBio, Inc. | 2025-11-11 |
| Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer (NCT06829823) | ImmunityBio, Inc. | 2025-11-01 |
| ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG (NCT06800963) | ImmunityBio, Inc. | 2025-10-15 |
| Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In (NCT06745908) | ImmunityBio, Inc. | 2025-10-01 |
| A Study to Examine Anktiva for the Treatment of COVID-19. (NCT07123727) | ImmunityBio, Inc. | 2025-09-04 |
| Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (NCT05618925) | ImmunityBio, Inc. | 2025-08-22 |
| A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia (NCT07556757) | ImmunityBio, Inc. | 2025-04-11 |
| A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer (NCT06710288) | ImmunityBio, Inc. | 2024-11-06 |
| Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma (NCT06334991) | ImmunityBio, Inc. | 2024-08-23 |
| N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma (NCT06061809) | ImmunityBio, Inc. | 2024-08-07 |
| IBRX-042 In Participants With HPV-Associated Tumors (NCT05976828) | ImmunityBio, Inc. | 2024-06-14 |
| Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis (NCT06040918) | ImmunityBio, Inc. | 2023-10-04 |
| Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC) (NCT05981131) | ImmunityBio, Inc. | 2023-08-17 |
| HCW9218 for Advanced Pancreatic Cancer (NCT05304936) | ImmunityBio, Inc. | 2022-10-17 |
| THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines (NCT05370040) | ImmunityBio, Inc. | 2022-05-05 |
| COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines (NCT04845191) | ImmunityBio, Inc. | 2021-12-01 |
| COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines (NCT04843722) | ImmunityBio, Inc. | 2021-12-01 |
| A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies (NCT04927884) | ImmunityBio, Inc. | 2021-09-08 |
| QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (NCT04898543) | ImmunityBio, Inc. | 2021-06-21 |
| COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults (NCT04710303) | ImmunityBio, Inc. | 2021-03-02 |
| COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA (NCT04732468) | ImmunityBio, Inc. | 2021-02-24 |
| A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL (NCT06022224) | ImmunityBio, Inc. | 2020-12-09 |
| COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers (NCT04591717) | ImmunityBio, Inc. | 2020-10-19 |
| Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation (NCT04397796) | ImmunityBio, Inc. | 2020-08-03 |
| Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19 (NCT04385849) | ImmunityBio, Inc. | 2020-07-22 |
| Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (NCT04390399) | ImmunityBio, Inc. | 2020-07-21 |
| QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy (NCT03853317) | ImmunityBio, Inc. | 2020-02-19 |
| QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma (NCT04052061) | ImmunityBio, Inc. | 2019-09-16 |
| QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers (NCT04050709) | ImmunityBio, Inc. | 2019-07-18 |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (NCT03228667) | ImmunityBio, Inc. | 2018-12-11 |
| QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine (NCT03563157) | ImmunityBio, Inc. | 2018-09-28 |
| QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (NCT03554109) | ImmunityBio, Inc. | 2018-09-01 |
| QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. (NCT03647423) | ImmunityBio, Inc. | 2018-08-31 |
| QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC (NCT03169777) | ImmunityBio, Inc. | 2018-08-01 |
| QUILT-3.088: NANT Pancreatic Cancer Vaccine (NCT03563144) | ImmunityBio, Inc. | 2018-08-01 |
| QUILT-3.080: NANT Pancreatic Cancer Vaccine (NCT03586869) | ImmunityBio, Inc. | 2018-07-17 |
| QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer (NCT03574649) | ImmunityBio, Inc. | 2018-06-01 |
| Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer (NCT03520686) | ImmunityBio, Inc. | 2018-05-18 |
| QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (NCT03387085) | ImmunityBio, Inc. | 2018-03-19 |
| QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors (NCT03169738) | ImmunityBio, Inc. | 2018-02-01 |
| QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed (NCT03387111) | ImmunityBio, Inc. | 2018-01-09 |
| QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (NCT03387098) | ImmunityBio, Inc. | 2017-12-28 |
| QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (NCT03197571) | ImmunityBio, Inc. | 2017-12-01 |
| QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy (NCT03167164) | ImmunityBio, Inc. | 2017-12-01 |
| QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy (NCT03167177) | ImmunityBio, Inc. | 2017-12-01 |
| QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy (NCT03175666) | ImmunityBio, Inc. | 2017-12-01 |
| QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL (NCT03169790) | ImmunityBio, Inc. | 2017-12-01 |
| QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy (NCT03197584) | ImmunityBio, Inc. | 2017-12-01 |
| QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (NCT03329248) | ImmunityBio, Inc. | 2017-11-06 |